The ordeal began in 2018 when MMJ Biopharma Cultivation submitted its application for a DEA bulk manufacturing registration (grow pharmaceutical marijuana). The company's objective was clear and ...

Duane Boise CEO of MMJ International Holdings stated, “When private citizens or companies fall short of compliance, the DEA acts swiftly ... stalled vital medical marijuana research, it's ...

The ordeal began in 2018 when MMJ Biopharma Cultivation submitted its application for a DEA bulk manufacturing registration (grow pharmaceutical marijuana). The company's objective was clear and ...

Critics contend that the DEA officials' alleged actions constitute a profound breach of public trust and raise serious legal and ethical concerns: Blatant Violation of Federal Law: H.R.8454 ...

The agency's sluggish processing of cultivation applications (mandated by the Medical Marijuana and Cannabidiol Research Expansion Act directly hinders MMJ's ability to proceed. Catch-22: The DEA ...

The DEA is proposing to increase the amount of marijuana that can be legally grown for research by 30% in 2020, a promising sign for cannabis advocates who have long insisted the plant has healing ...

The DEA may be close to reaching a decision on rescheduling marijuana to recognize the medical benefits. The DEA spokesman Russ Baer said no determination has been made yet on rescheduling pot, but ...

An administrative law judge nixed a DEA hearing on the proposed rescheduling of marijuana set to take place next week, pushing the hearing well into President-elect Donald Trump's next administration.

The DEA will move to reclassify marijuana as a Schedule III drug from its current standing as a Schedule I drug, according to a report from the AP that cites people familiar with the matter.

Some 36 states now permit marijuana to be used medically, and 17 allow recreational use. Yet researchers who wish to study the drug’s health effects have been limited since 1968 to a single legal ...